BioNTech names Sobi's Oelkers as CEO, succeeding Sahin by 2027

BioNTech is handing its CEO seat to Sobi's Guido Oelkers by February 2027 as co-founder Ugur Sahin exits to start a new mRNA company.

BioNTech SE (Nasdaq: BNTX) will hand its chief executive role to Sobi's Guido Oelkers no later than February 1, 2027, ending co-founder Ugur Sahin's run atop the German biotech that built the first widely used COVID-19 vaccine. The Mainz-based company's supervisory board appointed Oelkers, who has led Stockholm-listed Swedish Orphan Biovitrum since 2017, to succeed Sahin as it pushes toward a multi-product oncology franchise by 2030.

"Guido Oelkers is an experienced executive in the pharmaceutical industry," Helmut Jeggle, chairman of BioNTech's supervisory board, said. "His expertise in scaling innovation-driven organizations in a focused and capital-efficient manner will position the Company well to deliver on its key objectives to become a multi-product company."

Oelkers, a German citizen with a PhD in business management from Adelaide University, more than quadrupled Sobi's revenue over nine years through 2026 and built a career spanning BSN Medical, Gambro, Invida Holdings and Aventis Pharma China. He takes over a pipeline heavy on late-stage oncology assets — immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies — developed with partners including Bristol Myers Squibb, Genentech, Genmab and Pfizer.

The transition carries risk for investors. BioNTech shares plunged more than 20 percent in March when Sahin and chief medical officer Özlem Türeci said they would leave by year-end to start a new mRNA venture, and the stock still trades near a median analyst target of $130, according to Quiver data. Sahin will support Oelkers' onboarding before departing, while the search for Türeci's successor continues.

A Founder's Exit Reshapes the C-Suite

Sahin and Türeci, who married and co-founded BioNTech in 2008, will step down by the end of 2026 to lead a new, independent company focused on new mRNA applications. Their departure removes the scientific founders who steered the company from a research shop into a global vaccine maker, a shift that triggered the sharpest one-day selloff in the stock's history when it was announced in March. The supervisory board's search for Türeci's replacement as chief medical officer is ongoing, focused on a leader with late-stage clinical development experience.

What Oelkers Inherits

Oelkers takes the helm as BioNTech works to convert a deep clinical pipeline into approved products, with a stated goal of becoming a global biopharmaceutical company with multiple marketed drugs by 2030. The company's late-stage oncology work spans immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies, backed by collaborations with Bristol Myers Squibb, Duality Biologics, Genentech, Genmab, MediLink, OncoC4 and Pfizer. The oncology market is the largest therapy area in drug development, and BioNTech's mRNA platform — the technology behind its COVID-19 shot — is being repurposed toward personalized cancer vaccines.

For investors, the appointment points to continuity of strategy rather than a pivot: Oelkers' record at Sobi — where he more than quadrupled revenue over nine years — suggests a focus on commercial execution and capital discipline. With the stock trading near a median analyst target of $130 and the founders' exit already priced in after March's slide, the market's next test is whether Oelkers can deliver the pipeline milestones BioNTech has promised by 2030.

This article is for informational purposes only and does not constitute investment advice.